⚡ Metabolic Health Peptides

A GLP-1 receptor agonist and the gold standard for evidence-based weight loss peptide therapy. Demonstrated 14.9–16.9% mean body weight reduction in the landmark STEP trials.

Dose: 0.25–2.4 mg weekly (subcutaneous injection)

A dual GIP/GLP-1 receptor agonist that achieved up to 22.5% mean weight loss in the SURMOUNT-1 trial — the highest of any FDA-approved weight loss medication.

Dose: 2.5–15 mg weekly (subcutaneous injection)

The original once-daily GLP-1 receptor agonist. Lower weight-loss magnitude than semaglutide but a longer real-world track record across diabetes and obesity.

Dose: 0.6–3.0 mg daily (subcutaneous)

Triple agonist at GLP-1, GIP, and glucagon receptors. Phase 2 produced 24.2% mean weight reduction at 48 weeks — the highest ever in a clinical obesity trial.

Dose: Trial range: 1–12 mg weekly (subcutaneous)

A once-weekly amylin analog that reduces appetite via the area postrema. Combined with semaglutide ('CagriSema') it has produced ~22% weight loss in trial data.

Dose: Trial range: 0.16–4.5 mg weekly (subcutaneous)

A 16-amino-acid mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity in animal models. Among the most promising 'mitokines' for metabolic aging.

Dose: 5–10 mg, 2–3 times weekly (subcutaneous)

A dual GLP-1 / glucagon receptor agonist with strong Phase 2 weight-loss and MASH data. Resolution of MASH in 83% of participants at the highest dose at week 48.

Dose: Trial range: 0.6–6 mg weekly (subcutaneous)